Publications in Peer-Reviewed Journals
Brett J, Elshaug AG, Bhatia RS, Chalmers K et al. (2017). “A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study.” Implementation Science. 12:58
Nascimento A, Vidal AT, Almeida RT. (2016). “”Mapping stakeholders’ preferences in prioritization criteria for horizon scanning in healthcaremtechnologies.”” Cad. Saúde Pública, Rio de Janeiro, 32(7):e00177614
Parkinson B, Sermet C, Clement F, Crausaz S et al. (2016). Stratgies de dsinvestissement des produits pharmaceutiques: une revue de littrature internationale. Questions d’conomie de la sant n 220 – Juillet/aot 2016:1-8).
Parkinson B, Sermet C, Clement F, Crausaz S et al. (2015). “Value-Based Purchasing and Disinvestment Strategies for Pharmaceuticals: An International Review.” Pharmacoeconomics. 33(9):905-924
Godman B, Malmstrom RE, Diogene E, Jayathissa S et al. (2014). “Dabigatran – a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.” Front. Pharmacol 5
Godman B, Wettermark M, van Woerkom M, Fraeyman J et al. (2014). “Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.” Front Pharmacol 5: 106.
Moon JC, Godman B, Petzold M, Alvarez-Madrazo S et al. (2014). “Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications.” Frontiers in Pharmacology. 5 (Article 219):1-10
Baker DW, Qaseem A, Reynolds PP, Gardner LA et al. (2013). “Design and use of performance measures to decrease low-value services and achieve cost-conscious care.” Ann Intern Med 158(1): 55-59.
Watt AM, Willis CD, Hodgetts K, Elshaug AG, Hiller JE. (2013). “Engaging clinicians in evidence-based disinvestment: role and perceptions of evidence.” Int J Technol Assess Health Care 28(3): 211-219.
Carter D, Watt AM, Braunack-Mayer A, Elshaug A et al. (2013). “Should There Be a Female Age Limit on Public Funding for Assisted Reproductive Technology? Differing Conceptions of Justice in Resource Allocation.” Journal of Bioethical Inquiry, 10 (1), 79-91
Chamberlain CA, Martin RM, Busby J, Gilbert R et al. (2013). “Trends in procedures for infertility and caesarean sections: was NICE disinvestment guidance implemented?” NICE recommendation reminders. 6;13(1):112.
Garca-Armesto S, Campillo-Artero C, Bernal-Delgado E. (2013). “Disinvestment in the age of cost-cutting sound and fury. Tools for the Spanish National Health System.” Health Policy 110(2-3): 180-185.
Garner S, Docherty M, Somner J, Sharma T et al. (2013). “Reducing ineffective practice: challenges in identifying low-value health care using Cochrane systematic reviews.” J Health Serv Res Policy. 18(1):6-12.
Kiran T, Kopp A, Moineddin R, Victor JC et al. (2013). “Unintended consequences of delisting routine eye exams on retinopathy screening for people with diabetes in Ontario, Canada.” CMAJ. 185(3):E167-73
Scott, I. A. and Elshaug A. G. (2013). “Foregoing low-value care: how much evidence is needed to change beliefs?” Intern Med J 43(2): 107-109.
Cassel CK and Guest JA. (2012). “Choosing wisely: Helping physicians and patients make smart decisions about their care.” JAMA 307(17): 1801-1802.
Godman B, Malmstrom R, Bennie M, Sakshaug S et al. (2012). “Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency?” Reviews in Health Care 3(1).
Henshall C, Schuller T, Mardhani-Bayne L. (2012). “Using health technology assessment to support optimal use of technologies in current practice: the challenge of “disinvestment”.” Int J Technol Assess Health Care. 28(3):203-10.
Hodgetts K, Elshaug AG, Hiller JE. (2012).”What counts and how to count it: physicians’ constructions of evidence in a disinvestment context.” Hodgetts K, Elshaug AG, Hiller JE. Soc Sci Med. 75(12):2191-9.
Leggett L, Noseworthy TW, Zarrabi M, Lorenzetti D et al. (2012). “Health technology reassessment of non-drug technologies: current practices.” Int J Technol Assess Health Care 28(3): 220-227.
Qaseem A, Alguire P, Dallas P, Feinberg et al. (2012). “Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care.” Ann Intern Med 156(2): 147-149.
Robinson S, Dickinson H, Freeman T, Rumbold B, Williams I. (2012). “Structures and processes for priority-setting by health-care funders: a national survey of primary care trusts in England.” Halth Serv Manage Res. 25(3):113-20.
Robinson S, Williams I, Dickinson H, Freeman T et al. (2012). “Priority-setting and rationing in healthcare: evidence from the English experience.” (12):2386-93.
Smith N, Mitton C, Cornelissen E, Gibson J et al. (2012). “Using evaluation theory in priority setting and resource allocation.” J Health Organ Manag. 26(4-5):655-71.
Volpp KG, Loewenstein G, Asch DA. (2012). “Choosing wisely: low-value services, utilization, and patient cost sharing.” JAMA 308(16): 1635-1636.
Watt AM, Hiller JE, Braunack-Mayer AJ, Moss JR et al. (2012). “The ASTUTE Health study protocol: deliberative stakeholder engagements to inform implementation approaches to healthcare disinvestment.” Implement Sci. 22;7:101.
Wilt TJ and Qaseem A. (2012). Implementing high-value, cost-conscious diabetes mellitus care through the use of low-cost medications and less-intensive glycemic control target. Arch Intern Med. 12;172(20):1610-1.
Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E et al. (2011). “The ‘wise list’- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm.” Basic Clin Pharmacol Toxicol 108(4): 224-233.
Adamski J Godman, B, Ofierska-Sujkowska G, Osińska B et al. (2010). “Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.” BMC Health Services Research. 10:153
Godman B, Shrank W, Wettermark B, Andersen M et al. (2010). “Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?” Pharmaceuticals (Basel) 3(8): 2470-2494. (Supplementary Tables: click here)
Godman B, Shrank W, Andersen M, Berg C et al. (2010). “Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications.” Expert Rev Pharmacoecon Outcomes Res 10(6): 707-722.